|June 24, 2014|
|04:55 EDT||CRME, CRME, ALR, ALR, GALE, GALE, BIND, BIND, AVNR, AVNR, OCRX, OCRX, ONVO, ONVO, OSIR, OSIR, SGNT, SGNT, SNTA, SNTA, CRIS, CRIS||JMP Securities to hold a conference|
Healthcare Conference to be held in New York on June 24-25.
News For CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS From The Last 14 Days
Check below for free stories on CRME;SNTA;SGNT;OSIR;ONVO;OCRX;AVNR;BIND;GALE;ALR;CRIS the last two weeks.
|August 26, 2014|
|09:02 EDT||AVNR||Concert Pharmaceuticals achieves $2M milestone for AVP-786|
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. The agreement provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan compounds. The licensed compounds are believed to have potential for the treatment of neurological and psychiatric disorders. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined clinical, regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the second development milestone Concert has earned under the agreement.
|09:02 EDT||AVNR||Avanir initiates AVP-786 phase II study|
Subscribe for More Information
|August 25, 2014|
|14:01 EDT||CRME||Cardiome enters agreement with Eurolab Especialidades Medicinales |
Cardiome Pharma announced that its subsidiary, Correvio International SÓrl, has entered into an agreement with Eurolab Especialidades Medicinales de Eurofar S.R.L. to sell and distribute BRINAVESS exclusively in Argentina. Under the terms of the agreement, Eurolab has agreed to specific annual commercial goals for BRINAVESS. Financial details of the agreement have not been disclosed.
|August 22, 2014|
|12:39 EDT||AVNR||These five companies will benefit from increased ALS awareness, MarketWatch says|
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
|August 21, 2014|
|07:15 EDT||GALE||Galena announces resignation of CEO Mark Ahn|
Galena Biopharma announced that Mark Schwartz, Ph.D., has been appointed as President and CEO, effective immediately. Dr. Schwartz was previously Galena's COO. He replaces Mark Ahn, Ph.D. who has resigned as the President and CEO and as a director of the company to pursue "other long held personal and professional goals." It is expected that Dr. Schwartz will also be appointed to Galena's board.
|05:32 EDT||GALE||Galena fired CEO over stock promotion scandal, Feuerstein says|
Galena fired its CEO Mark Ahn following a stock promotion scandal, The Street's Adam Feuerstein reported last night, citing a source close to the company. A public announcement is coming today, Feuerstein added.
|August 14, 2014|
|10:53 EDT||ALR||High option volume stocks|
Subscribe for More Information